Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction alpha-3 protein (GJA3), also known as connexin-46, is a connexin family ion channel protein predominantly expressed in the lens fiber cells of the eye[1][4][5]. It assembles into gap junction channels forming dodecameric complexes that allow the passage of ions and small metabolites—including antioxidants—between cells, thereby maintaining lens transparency and homeostasis[1][4]. Disruptions in GJA3, particularly missense mutations, have been repeatedly linked to autosomal dominant congenital cataracts through impaired gap junction communication and loss of lens cellular homeostasis[1][3][5]. The function of GJA3 is essential for normal lens growth, differentiation, and metabolic coupling, and altered function is a clear cause of specific inherited cataract phenotypes, but GJA3 is not currently considered a common or direct therapeutic target in drug development[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction alpha-3 protein (GJA3).